Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WH002 vs Paclitaxel in HER2-Negative Breast Cancer
NCT06513364Phase 2Completed
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of WH002 in breast cancer (2 arms), sponsored by Beijing Wehand-Bio Pharmaceutical Co., Ltd. Primary endpoint: Adverse Events and Serious Adverse Events. Started Sep 2024; status: completed.
02
Drugs
WH002
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06513364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513364.